Pathophysiology of delayed cerebral ischemia after subarachnoid hemorrhage: a review
Delayed cerebral ischemia is a major predictor of poor outcomes in patients who suffer
subarachnoid hemorrhage. Treatment options are limited and often ineffective despite many …
subarachnoid hemorrhage. Treatment options are limited and often ineffective despite many …
Delayed cerebral ischemia after subarachnoid hemorrhage
Delayed cerebral ischemia (DCI) is the most feared complication of aneurysmal
subarachnoid hemorrhage (aSAH). It increases the mortality and morbidity associated with …
subarachnoid hemorrhage (aSAH). It increases the mortality and morbidity associated with …
Antiplatelet management for stent-assisted coiling and flow diversion of ruptured intracranial aneurysms: a DELPHI consensus statement
BACKGROUND AND PURPOSE: There is a paucity of data regarding antiplatelet
management strategies in the setting of stent-assisted coiling/flow diversion for ruptured …
management strategies in the setting of stent-assisted coiling/flow diversion for ruptured …
Trends in dual antiplatelet therapy use for neurointerventional procedures for the management of intracranial aneurysms
The use of periprocedural dual antiplatelet therapy (DAPT) has significantly evolved along
with innovations in the endovascular management of intracranial aneurysms. Historically …
with innovations in the endovascular management of intracranial aneurysms. Historically …
Ginsenoside Rh4 inhibits breast cancer growth through targeting histone deacetylase 2 to regulate immune microenvironment and apoptosis
F Dong, L Qu, Z Duan, Y He, X Ma, D Fan - Bioorganic Chemistry, 2023 - Elsevier
High expression of histone deacetylase 2 (HDAC2) is recognized as a marker of invasive
breast cancer (BC). HDAC2 is not only responsible for enhancing tumor cell growth …
breast cancer (BC). HDAC2 is not only responsible for enhancing tumor cell growth …
An updated review on glycoprotein IIb/IIIa inhibitors as antiplatelet agents: basic and clinical perspectives
Abstract The glycoprotein (GP) IIb/IIIa receptor is found integrin present in platelet
aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived …
aggregations. GP IIb/IIIa antagonists interfere with platelet cross-linking and platelet-derived …
Role of platelets in the pathogenesis of delayed injury after subarachnoid hemorrhage
Aneurysmal subarachnoid hemorrhage (aSAH) patients develop delayed cerebral ischemia
and delayed deficits (DCI) within 2 weeks of aneurysm rupture at a rate of approximately …
and delayed deficits (DCI) within 2 weeks of aneurysm rupture at a rate of approximately …
Endovascular therapy versus microsurgical clipping of unruptured wide-neck aneurysms: a prospective multicenter study with propensity score analysis
OBJECTIVE Numerous techniques have been developed to treat wide-neck aneurysms
(WNAs), each with different safety and efficacy profiles. Few studies have compared …
(WNAs), each with different safety and efficacy profiles. Few studies have compared …
The use of cangrelor in neurovascular interventions: a multicenter experience
Purpose Thromboembolic events represent the most common procedure-related
complication associated with neurointerventions. Cangrelor is a potent, intravenous (IV) …
complication associated with neurointerventions. Cangrelor is a potent, intravenous (IV) …
Use of Tirofiban to Prevent Ischemic Events in Patients with CYP2C19 Loss-of-Function Alleles during Flow Diversion of Intracranial Aneurysm: A Multicenter Cohort …
Y Zhou, H Kang, W Li, B Luo, C Wang, R Xie… - Translational stroke …, 2024 - Springer
To analyze the effect of tirofiban on ischemic events in CYP2C19 loss-of-function (LOF)
allele carriers during pipeline embolization device (PED) implantation. Demographic …
allele carriers during pipeline embolization device (PED) implantation. Demographic …